drugset / Trial / NCT05597722

Addressing Cognitive Fog in Long-COVID-19 Patients

NCT05597722

Phase 4 Terminated 7 enrolled Eva Szigethy The Beckwith Institute · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID. Long-COVID is post-COVID conditions or symptoms lasting more than four weeks after infection. Clinicians from the UPMC Long-COVID Clinic leading this study are evaluating the utility of computer-based evaluation of COVID-related cognitive fog and the helpfulness of two intervention strategies to treat moderate cognitive impairment using a randomized trial. The two intervention strategies include 1) a standardized dosing of amphetamine/dextroamphetamine medication that has been used to improve cognitive fog; and 2) a digital behavioral tool with an embedded health coach that is used on a mobile phone.

Timeline

Start
2023-04-04
Primary completion
2023-05-18
Completion
2023-05-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 10 mg